Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Emerging trends for pancreatitis in the scientific literature: a new report

Posted on October 19th, 2021 by

Pharma R&D

Elsevier has just released the Emerging trends for pancreatitis in the scientific literature report, which identifies proteins and genes linked to pancreatitis. Elsevier’s Professional Services team prepared it pro bono for Mission: Cure, a foundation that is focused on finding a disease-modifying treatment for pancreatitis. The team hopes that all researchers working on pancreatitis, which affects millions of people worldwide in both acute and chronic forms, will find it useful.

(more…)

Finding drug information can be hard – healthcare providers need digital solutions

Posted on October 5th, 2021 by

Medical Information

The digital transformation in our world was already happening quite rapidly in recent years, but then the COVID-19 pandemic accelerated many aspects of it. Not only did schools and businesses have to learn to function online, but everything from doctor’s visits to dance parties were frequently being conducted on the internet. But even as many sectors have made the digital transition, some areas have continued to lag behind.

(more…)

AI precision medicine accelerates the search for rare disease treatment

Posted on September 20th, 2021 by

AI & Data

AI and precision medicine are both changing drug discovery and development as we know it. Precision medicine that is powered by AI stands to be transformative, especially for the treatment of rare diseases. Elsevier was recently part of a collaboration that sought to demonstrate how AI precision medicine could lead researchers to new treatments for brain tumors faster.

(more…)

At the leading edge of an innovation hotspot: predictive reaction modeling

Posted on September 8th, 2021 by

Chemistry

Indisputably, a surge in predictive machine learning models to support synthetic chemistry has galvanized a movement to make these tools effective R&D solutions. Reaxys has been part of this innovation journey from the beginning. Today, Reaxys includes an award-winning Predictive Retrosynthesis solution that merges deep neural networks trained on Reaxys data with a Monte Carlo tree search to quickly discover promising candidate routes. Users explore these routes and new synthetic spaces via an intuitive interface that links to Reaxys content on commercial availability and accelerates design-make-test-analyze (DMTA) cycles.

(more…)

Companies pledge to become net zero by 2040

Posted on August 31st, 2021 by

Chemistry

The Intergovernmental Panel on Climate Change (IPCC) just released a special report on the impacts of climate change, and the findings suggest a very concerning picture of the future if greenhouse gas emissions continue at the current rate. The drastic changes in the weather, driving everything from wildfires to drought, are already giving us a preview of an increasingly turbulent future – and the knock-on effects can be seen in resulting crises like the large-scale loss of crops and homes.

(more…)

Lessons learned from the Covid vaccine development process

Posted on August 23rd, 2021 by

COVID-19

As the world’s focus has turned to getting the COVID-19 vaccines out as widely and rapidly as possible, it’s easy to almost forget about the incredible global effort that developed them in record time. But it is important to take some time to reflect on the process that got us here, so that we can learn from it and celebrate the amazing researchers whose work is now saving so many lives.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 86

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.